Compare GCO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | ALLO |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.2M | 452.6M |
| IPO Year | 1994 | 2018 |
| Metric | GCO | ALLO |
|---|---|---|
| Price | $36.44 | $1.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $39.67 | $9.00 |
| AVG Volume (30 Days) | 86.4K | ★ 5.7M |
| Earning Date | 12-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.38 | $223.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.71 | N/A |
| 52 Week Low | $21.93 | $1.04 |
| 52 Week High | $43.60 | $4.46 |
| Indicator | GCO | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 29.35 |
| Support Level | $31.83 | $1.22 |
| Resistance Level | $38.29 | $2.22 |
| Average True Range (ATR) | 1.20 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 45.02 | 26.56 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).